WHAT IS SCINTIMAMMOGRAPHY (MIRALUMA, SESTAMIBI BREAST IMAGING, RADIONUCLIDE BREAST IMAGING) TEST?

WHAT IS SCINTIMAMMOGRAPHY (MIRALUMA, SESTAMIBI BREAST IMAGING, RADIONUCLIDE BREAST IMAGING) TEST?

A nuclear medicine planar scan in which a radioisotope, technetium-99m sestamibi (Miraluma99mTc-sestamibi, 99mTc-MIBI), is used to provide pictures of breast lesions. A “trace” amount of the radioisotope (producing a low dose of radiation) is injected intravenously and accumulates in areas of increased metabolic activity, such as that found in malignant cells. Images of each breast are taken by a gamma (Anger) camera to identify any areas of focal uptake of the isotope, indicating the possible presence of a cancerous lesion. A high-resolution method of this procedure has been shown to be more sensitive than a conventional camera for differentiating indeterminate breast lesions but is still inferior to biopsy. However, this test has a high negative predictive value (93%), making it valuable in reducing the number of negative breast biopsies. Sensitivity is 87.8%, specificity 92.8% and positive predictive value 96.6%. 

(Visited 2 times, 1 visits today)
KNOWLEDGE BASE
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

X